Concert Pharmaceuticals Company Profile (NASDAQ:CNCE)

Analyst Ratings

Consensus Ratings for Concert Pharmaceuticals (NASDAQ:CNCE) (?)
Ratings Breakdown: 6 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $26.50 (126.50% upside)

Analysts' Ratings History for Concert Pharmaceuticals (NASDAQ:CNCE)
Show:
DateFirmActionRatingPrice TargetActions
7/11/2016Brean CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/1/2016Stifel NicolausInitiated CoverageBuy$23.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$28.00 -> $24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$28.00 -> $24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/26/2016AegisReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/8/2015Roth CapitalInitiated CoverageBuy$32.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/24/2015Ladenburg ThalmannBoost Price TargetBuy$24.00 -> $27.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/26/2014 forward)

Earnings

Earnings History for Concert Pharmaceuticals (NASDAQ:CNCE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/3/2016        
5/5/2016Q116($0.45)($0.63)$1.24 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/1/2016Q415($0.05)$0.03$11.24 million$10.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($0.41)($0.39)$4.50 million$1.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2015Q215($0.46)$1.80$1.66 million$3.25 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2015Q115($0.38)($0.48)$2.70 million$1.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/27/2015Q414($0.60)($0.48)$1.38 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2014Q314($0.49)($0.43)$1.67 million$4.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2014Q214($0.42)($0.45)$1.30 million$1.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/14/2014Q114($0.49)($0.76)$0.44 million$1.61 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Concert Pharmaceuticals (NASDAQ:CNCE)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Concert Pharmaceuticals (NASDAQ:CNCE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Concert Pharmaceuticals (NASDAQ:CNCE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/12/2016Thomas G AuchinclossDirectorBuy2,000$10.11$20,220.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/11/2016Roger D TungCEOBuy19,610$10.55$206,885.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/16/2015Wilfred E JaegerDirectorSell10,360$19.57$202,745.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2015Wilfred E JaegerDirectorSell54,572$20.10$1,096,897.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/14/2015Pauline McgowanVPSell498$20.07$9,994.86View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/14/2015Wilfred E JaegerDirectorSell3,922$20.09$78,792.98View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/9/2015Ronald W. BarrettDirectorSell17,699$22.27$394,156.73View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/2/2015Nancy StuartCOOSell23,216$24.29$563,916.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/18/2015Robert SilvermanVPSell10,000$20.00$200,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2015Wilfred E JaegerDirectorSell120,000$18.22$2,186,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2015Wilfred E JaegerDirectorSell760,000$15.81$12,015,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2015Wilfred E JaegerDirectorSell92,215$16.75$1,544,601.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/12/2015Wilfred E JaegerDirectorSell97,785$17.49$1,710,259.65View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2015Robert SilvermanVPSell5,000$16.35$81,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/11/2015Nancy StuartCOOSell46,430$15.00$696,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/11/2015Pauline McgowanVPSell5,973$16.00$95,568.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/10/2015Pauline McgowanVPSell22,122$13.90$307,495.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/18/2014Three Arch Management Iv, L.L.DirectorSell250,000$12.29$3,072,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/20/2014Skyline Venture Partners QualiMajor ShareholderBuy150,000$14.00$2,100,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/19/2014Life Science Ventures Vi G TvmDirectorBuy89,000$14.00$1,246,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/19/2014Plc GlaxosmithklineMajor ShareholderBuy35,000$14.00$490,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Concert Pharmaceuticals (NASDAQ:CNCE)
DateHeadline
07/22/16 10:35 AMConcert Pharmaceuticals, Inc. (NASDAQ:CNCE): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/20/16 10:39 PMEarnings Focus and Crowd Sourced Sentiment Review for Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) - TGP
07/20/16 10:39 PMHeightened Volatility Spotted on Shares of: Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) - Engelwood Daily
07/17/16 07:55 AMBvf INC Increased Concert Pharmaceuticals INC (NASDAQ:CNCE) by $6.80 Million as Shares Declined - Consumer Eagle
07/17/16 07:55 AMShares Moving Down on the Week: Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) - Engelwood Daily
07/16/16 03:14 PMHow Analysts Rated Concert Pharmaceuticals Inc (NASDAQ:CNCE) Last Week? - Consumer Eagle
07/16/16 05:58 AMShares Experiencing a Downtrend: Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) - TGP
07/15/16 09:59 AMConcert Pharmaceuticals Inc's Stock Is Sell After Today's Huge Decline - Press Telegraph
07/15/16 09:59 AMNew Broker Ratings For Concert Pharmaceuticals Inc (CNCE) - FTSE News
07/15/16 09:59 AMConcert Pharmaceuticals, Inc. (NASDAQ:CNCE) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/14/16 08:50 PMConcert Pharmaceuticals Incorporated (NASDAQ:CNCE) Shorted Shares Decreased By 11.37% - Press Telegraph
07/13/16 08:40 PMInsiders Increasing Positions in: Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) - Press Telegraph
07/13/16 11:23 AMConcert Pharmaceuticals, Inc. (NASDAQ:CNCE) Wall Street Analyst Recommendation Outlook - Telanagana Press
07/13/16 11:23 AMCONCERT PHARMACEUTICALS (NASDAQ:CNCE) Institutional Investors Sentiment - Consumer Eagle
07/13/16 11:23 AMBroker Outlook For Concert Pharmaceuticals Inc (CNCE) - Fiscal Standard
07/12/16 07:33 AMWill Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Surprise Analysts? - Investor Newswire
07/10/16 07:54 AMConcert Pharmaceuticals Incorporated (NASDAQ:CNCE) Shorts Decreased by 11.37% After Short Covering - Engelwood Daily
07/10/16 07:54 AMConcert Pharmaceuticals Inc (CNCE) Broker Price Targets For The Coming Week - Fiscal Standard
07/09/16 05:46 AMBvf INC Increased Concert Pharmaceuticals INC (NASDAQ:CNCE) by $6.80 Million as Shares Declined - Press Telegraph
07/08/16 10:58 AMCompany Stock Focus for Concert Pharmaceuticals, Inc. (NASDAQ:CNCE): Which Way Will Shares Head? - Press Telegraph
07/07/16 03:18 PMConcert Pharmaceuticals Announces Webcast at Cantor Fitzgerald Healthcare Conference - Yahoo Finance
07/07/16 10:48 AMStock Tracking Down This Month; Investor Alert on Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) - Engelwood Daily
07/06/16 06:11 AMConcert Pharmaceuticals Announces Webcast at Cantor Fitzgerald Healthcare Conference - [at noodls] - LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the Cantor Fitzgerald Healthcare Conference on Wednesday, July ...
07/04/16 08:09 AMCould Concert Pharmaceuticals Inc Decrease Even More? The Stock Formed Bearish Wedge Down Chart Pattern - Engelwood Daily
07/01/16 06:00 AMCoverage initiated on Concert Pharmaceuticals by Stifel -
06/30/16 08:44 PMConcert Pharmaceuticals, Inc. (NASDAQ:CNCE) Company Rating and Target Watch - Telanagana Press
06/28/16 03:17 PMShare Update and Earnings Review for Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) - Press Telegraph
06/28/16 03:17 PMA Look At Concert Pharmaceuticals - Seeking Alpha
06/24/16 03:25 PMConcert Pharmaceuticals, Inc. (NASDAQ:CNCE) Earnings Glance and Target Price Review - Engelwood Daily
06/24/16 07:02 AMConcert Pharmaceuticals Inc (CNCE) Updated Price Targets - FTSE News
06/24/16 07:02 AMCovering the Bases on Concert Pharmaceuticals, Inc. (NASDAQ:CNCE): Where is the Stock Going? - Press Telegraph
06/22/16 03:27 PMConcert Pharmaceuticals Inc (CNCE) Current Analyst Ratings - Fiscal Standard
06/10/16 03:13 PMCONCERT PHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/10/16 11:21 AMConcert Pharma (CNCE) Announces Results from CTP-656 Phase 1 in CF; Superior PK Profile Noted - StreetInsider.com
06/10/16 09:49 AMConcert Pharmaceuticals Presents CTP-656 Phase 1 Results at European Cystic Fibrosis Conference - [at noodls] - Findings Confirmed Superior Pharmacokinetic Profile Relative to Kalydeco LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today presented results from a Phase 1 multiple ...
06/08/16 11:52 AMCONCERT PHARMACEUTICALS INC. (NASDAQ:CNCE) Financial Condition Compared to S&P 500 - CML News
06/06/16 06:43 AMConcert Pharmaceuticals Incorporated (NASDAQ:CNCE) Shorts Decreased by 12.56% After Short Covering - HNN
06/05/16 11:06 AMConcert Pharmaceuticals Inc (CNCE) Broker Price Targets For The Coming Week - Share Trading News
06/03/16 09:26 PMBvf INC Increased Concert Pharmaceuticals INC (NASDAQ:CNCE) by $6.80 Million as Shares Declined - CCH Daily News
06/03/16 03:27 PMConcert Pharmaceuticals, Inc. (NASDAQ:CNCE) Stock Update & Estimates - Stock Tick Tock
06/03/16 11:51 AMShare Rating Focus on Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) - HNN
06/02/16 11:28 AMTarget Price and Stock Performance Rundown for Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) - HNN - Target Price and Stock Performance Rundown for Concert Pharmaceuticals, Inc. (NASDAQ:CNCE)HNNDuring the latest trading session, Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) shares traded +2.10%. Monitoring the stock price relative to moving averages may offer enhanced perspective on stock performance. After a recent check, shares have been ...and more »
06/01/16 11:48 AMBroker Watchlist: Concert Pharmaceuticals Inc (CNCE) - Share Trading News - Broker Watchlist: Concert Pharmaceuticals Inc (CNCE)Share Trading News03/10/2014 – Wells Fargo began new coverage on Concert Pharmaceuticals Inc giving the company a “outperform” rating. The share price of Concert Pharmaceuticals Inc (CNCE) was down -0.82% during the last trading session, with a day high of 13.65.and more »
05/31/16 03:22 PMConcert Pharmaceuticals: Huge Value Hidden In This Microcap Gem - Seeking Alpha - Concert Pharmaceuticals: Huge Value Hidden In This Microcap GemSeeking AlphaA recently published article on Seeking Alpha did an excellent job of describing and analyzing Concert Pharmaceuticals' (NASDAQ:CNCE) intellectual property and drug pipeline. We will not reinvent the wheel in this article but rather attempt to inject ...
05/31/16 08:39 AMConcert Pharmaceuticals Inc (CNCE) Given “Buy” Rating at Brean Capital - Let Me Know About This - Concert Pharmaceuticals Inc (CNCE) Given “Buy” Rating at Brean CapitalLet Me Know About ThisConcert Pharmaceuticals Inc logo Brean Capital reaffirmed their buy rating on shares of Concert Pharmaceuticals Inc (NASDAQ:CNCE) in a research report released on Tuesday. In related news, CEO Roger D. Tung purchased 19,610 shares of the firm's ...and more »
05/27/16 06:51 PMHow Analysts Feel About Concert Pharmaceuticals Inc (NASDAQ:CNCE)? - Wall Street Hints and News - How Analysts Feel About Concert Pharmaceuticals Inc (NASDAQ:CNCE)?Wall Street Hints and NewsThis means NaN are positive. Concert Pharmaceuticals has been the topic of 8 analyst reports since August 12, 2015 according to StockzIntelligence Inc. Below is a list of Concert Pharmaceuticals Inc (NASDAQ:CNCE) latest ratings and price target changes.and more »
05/27/16 10:02 AMStock Rating Review for Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) - Wall Street Hints and News - Stock Rating Review for Concert Pharmaceuticals, Inc. (NASDAQ:CNCE)Wall Street Hints and NewsCovering equity analysts presently have a consensus stock rating of 1 on shares of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). Covering analysts will often provide Sell, Hold, or Buy recommendations based on their advanced research. This consensus ...and more »
05/26/16 07:28 AMTarget Check and Stock Performance Recap Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) - Wall Street Hints and News - Target Check and Stock Performance Recap Concert Pharmaceuticals, Inc. (NASDAQ:CNCE)Wall Street Hints and NewsTracking stock performance from various views may help with share evaluation. Some investors might be more focused on short-term share action while others may prefer to view long-term performance. In recent session activity, Concert Pharmaceuticals, Inc.and more »
05/20/16 10:26 AMAnalyst Rating Check on Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) - Wall Street Hints and News - Analyst Rating Check on Concert Pharmaceuticals, Inc. (NASDAQ:CNCE)Wall Street Hints and NewsCurrently, sell-side analysts have provided a consensus stock rating of 1 on shares of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). Analysts that cover the company will usually offer Buy, Sell, or Hold recommendations based on in-depth research.and more »
05/19/16 11:48 PMShare Performance and Target Price Review for Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) - Wall Street Hints and News - Share Performance and Target Price Review for Concert Pharmaceuticals, Inc. (NASDAQ:CNCE)Wall Street Hints and NewsLooking at stock activity from multiple angles may be of benefit when examining share performance. Investors have the ability to focus in on short or long term share performance. During the most recent trading session, Concert Pharmaceuticals, Inc.and more »

Social

About Concert Pharmaceuticals

Concert Pharmaceuticals logoConcert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others segment. It has clinical candidates under development, including AVP-786, CTP-656, CTP-730 and JZP-386. The Company's deuterated chemical entity platform (DCE Platform) enables it to identify compounds for deuteration and to design, evaluate, develop and manufacture deuterated compounds. The Company is utilizing its DCE Platform to discover and develop product candidates for a range of indications. The Company's product candidate, CTP-656, is a next generation potentiator that the Company is initially developing for the treatment of cystic fibrosis in patients having gating mutations, including the G551D mutation. AVP-786 is a combination of a deuterated dextromethorphan analog and a low dose of quinidine.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CNCE
  • CUSIP:
Key Metrics:
  • Previous Close: $11.70
  • 50 Day Moving Average: $11.76
  • 200 Day Moving Average: $13.31
  • P/E Ratio: 14.05
  • P/E Growth: 0.00
  • Market Cap: $259.93M
  • Beta: 1.45
  • Current Year EPS Consensus Estimate: $-2.34 EPS
  • Next Year EPS Consensus Estimate: $-1.89 EPS
Additional Links:
Concert Pharmaceuticals (NASDAQ:CNCE) Chart for Tuesday, July, 26, 2016